TL
Telix Pharmaceuticals Limited (TLX)
NASDAQ·Healthcare·Biotechnology
$10.44
+0.38%
Mkt Cap $2.54B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 19, 2026 | $418.49M | $413.40M | -1.22% | $0.03 | -$0.01 | -135.40% | — | — |
| Q3 2025 Aug 20, 2025 | $322.87M | $388.59M | +20.35% | $0.13 | -$0.01 | -105.07% | — | — |
| Q1 2025 Feb 20, 2025 | $135.06M | $367.80M | +172.32% | $0.09 | $0.07 | -25.16% | — | — |
| Q3 2024 Aug 22, 2024 | $237.81M | $125.99M | -47.02% | $0.09 | $0.02 | -74.99% | — | — |
| Q4 2023 Dec 31, 2023 | $112.59M | $191.79M | +70.34% | — | $0.04 | — | — | — |
| Q2 2023 Jun 30, 2023 | $146.90M | $146.66M | -0.17% | $0.04 | -$0.03 | -179.86% | — | — |
| Q4 2022 Dec 31, 2022 | $86.96M | $92.98M | +6.92% | -$0.05 | -$0.07 | -45.55% | — | — |
| Q2 2022 Jun 30, 2022 | $20.37M | $16.53M | -18.82% | -$0.08 | -$0.16 | -92.73% | — | — |
| Q4 2021 Dec 31, 2021 | $2.39M | $3.40M | +42.40% | -$0.05 | -$0.12 | -126.58% | — | — |
| Q2 2021 Jun 30, 2021 | — | $2.18M | — | — | -$0.09 | — | — | — |
| Q4 2020 Dec 31, 2020 | — | $2.77M | — | — | -$0.08 | — | — | — |
| Q2 2020 Jun 30, 2020 | — | $1.11M | — | — | -$0.05 | — | — | — |
| Q4 2019 Dec 31, 2019 | $4.74M | $5.22M | +10.15% | -$0.09 | -$0.10 | -10.98% | — | — |
| Q2 2019 Jun 30, 2019 | $3.67M | $3.75M | +2.04% | $0.02 | $0.02 | -11.89% | — | — |
| Q4 2018 Dec 31, 2018 | $3.15M | $3.35M | +6.25% | -$0.18 | -$0.25 | -35.82% | — | — |
| Q2 2018 Jun 30, 2018 | $2.97M | $3.06M | +3.12% | -$0.70 | -$0.02 | +97.22% | — | — |
| Q4 2017 Dec 31, 2017 | $15.48M | $37.58K | -99.76% | -$1.53 | -$0.01 | +99.04% | — | — |
| Q2 2017 Jun 30, 2017 | $3.98M | $3.98M | +0.01% | $0.00 | $0.00 | +7.41% | — | — |
| Q1 2017 Jan 31, 2017 | — | — | — | — | -$0.01 | — | — | — |
| Q4 2016 Dec 31, 2016 | $5.68M | $5.72M | +0.83% | $0.22 | $0.17 | -25.79% | — | — |